Ondibta is a medicine used to treat adults, adolescents and children from 2 years of age with diabetes. Ondibta contains the active substance insulin glargine and is a biological medicine. It is a ‘biosimilar medicine’; this means that Ondibta is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Ondibta is Lantus.
Therapeutic Indication
Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Therapeutic Area (MeSH)
ATC Code
A10AE04
ATC Item
N/A
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
INN / Common Names
EMA Name
Ondibta
Medicine Name
Ondibta
Aliases
N/ANo risk management plan link.
